Surveillance, Epidemiology, and End Results Program. Cancer stat facts: ovarian cancer. Accessed July 21, 2022. Available at: https://seer.cancer.gov/statfacts/html/ovary.html
Terplan M, Schluterman N, McNamara EJ, et al. Have racial disparities in ovarian cancer increased over time? An analysis of SEER data. Gynecol Oncol 2012;125:19–24.
Barnholtz-Sloan JS, Tainsky MA, Abrams J, et al. Ethnic differences in survival among women with ovarian carcinoma. Cancer 2002;94:1886–1893.
Bristow RE, Chang J, Ziogas A, et al. Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status. Gynecol Oncol 2014;134:60–67.
Bristow RE, Powell MA, Al-Hammadi N, et al. Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J Natl Cancer Inst 2013;105:823–832.
Harlan LC, Clegg LX, Trimble EL. Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 2003;21:3488–3494.
Parham G, Phillips JL, Hicks ML, et al. The National Cancer Data Base report on malignant epithelial ovarian carcinoma in African-American women. Cancer 1997;80:816–826.
Armstrong DK, Alvarez RD, Backes FJ, et al. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. Version 3.2022. Accessed July 21, 2022. To view the most recent version, visit https://www.nccn.org
Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248–1259.
Farley JH, Tian C, Rose GS, et al. Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials. Cancer 2009;115:4210–4217.
Winter WE III, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007;25:3621–3627.
Penchansky R, Thomas JW. The concept of access: definition and relationship to consumer satisfaction. Med Care 1981;19:127–140.
Karanth S, Fowler ME, Mao X, et al. Race, socioeconomic status, and health-care access disparities in ovarian cancer treatment and mortality: systematic review and meta-analysis. JNCI Cancer Spectr 2019;3:pkz084.
Long B, Chang J, Ziogas A, et al. Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California. Am J Obstet Gynecol 2015;212:468.e1–468.e9.
Hodeib M, Chang J, Liu F, et al. Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer. Gynecol Oncol 2015;138:121–127.
Goldberg EM, Berger Y, Sood D, et al. Differences in sociodemographic disparities between patients undergoing surgery for advanced colorectal or ovarian cancer. Ann Surg Oncol 2021;28:7795–7806.
Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: an overview. Med Care 2002;40(Suppl):IV-26–35.
Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130–1139.
Morgan RJ Jr, Alvarez RD, Armstrong DK, et al. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. Version 2.2013. J Natl Compr Canc Netw 2013;11:1199–1209.
Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702–706.
Howell EA, Egorova N, Hayes MP, et al. Racial disparities in the treatment of advanced epithelial ovarian cancer. Obstet Gynecol 2013;122:1025–1032.
Taylor JS, He W, Harrison R, et al. Disparities in treatment and survival among elderly ovarian cancer patients. Gynecol Oncol 2018;151:269–274.
Bandera EV, Lee VS, Rodriguez-Rodriguez L, et al. Racial/ethnic disparities in ovarian cancer treatment and survival. Clin Cancer Res 2016;22:5909–5914.
Terplan M, Smith EJ, Temkin SM. Race in ovarian cancer treatment and survival: a systematic review with meta-analysis. Cancer Causes Control 2009;20:1139–1150.
Long B, Chang J, Ziogas A, et al. Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California. Am J Obstet Gynecol 2015;212:468.E1–468.E9.
Bristow RE, Chang J, Ziogas A, et al. Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines. Obstet Gynecol 2015;125:833–842.
Bristow RE, Zahurak ML, Ibeanu OA. Racial disparities in ovarian cancer surgical care: a population-based analysis. Gynecol Oncol 2011;121:364–368.
Bristow RE, Chang J, Ziogas A, et al. Adherence to treatment guidelines for ovarian cancer as a measure of quality care. Obstet Gynecol 2013;121:1226–1234.
Austin S, Martin MY, Kim Y, et al. Disparities in use of gynecologic oncologists for women with ovarian cancer in the United States. Health Serv Res 2013;48:1135–1153.
Bristow RE, Chang J, Ziogas A, et al. High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. Gynecol Oncol 2014;132:403–410.
Cronin KA, Howlader N, Stevens JL, et al. Racial disparities in the receipt of guideline care and cancer deaths for women with ovarian cancer. Cancer Epidemiol Biomarkers Prev 2019;28:539–545.
Ulmer KK, Greteman B, Cardillo N, et al. Disparity of ovarian cancer survival between urban and rural settings. Int J Gynecol Cancer 2022;32:540–546.
Casagrande SS, Gary TL, LaVeist TA, et al. Perceived discrimination and adherence to medical care in a racially integrated community. J Gen Intern Med 2007;22:389–395.
Jacobs EA, Rathouz PJ, Karavolos K, et al. Perceived discrimination is associated with reduced breast and cervical cancer screening: the Study of Women’s Health Across the Nation (SWAN). J Womens Health (Larchmt) 2014;23:138–145.
Mullins MA, Peres LC, Alberg AJ, et al. Perceived discrimination, trust in physicians, and prolonged symptom duration before ovarian cancer diagnosis in the African American Cancer Epidemiology Study. Cancer 2019;125:4442–4451.
- Search Google Scholar
- Export Citation
, Mullins MA , Peres LC , Alberg AJ Perceived discrimination, trust in physicians, and prolonged symptom duration before ovarian cancer diagnosis in the African American Cancer Epidemiology Study. Cancer 2019; 125: 4442– 4451. 31415710 10.1002/cncr.32451
Starbuck KD, Szender JB, Duncan WD, et al. Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer. PLoS One 2018;13:e0206913.
Wright J, Doan T, McBride R, et al. Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. Br J Cancer 2008;98:1197–1203.
Denduluri N, Lyman GH, Wang Y, et al. Chemotherapy dose intensity and overall survival among patients with advanced breast or ovarian cancer. Clin Breast Cancer 2018;18:380–386.